SCHEDULE: Fosun Entities Disclose 4.7% Stake in Butterfly Network

Fosun Industrial and Shanghai Fosun Pharmaceutical Group report a combined 4.7% beneficial ownership in Butterfly Network's Class A common stock.

Summary

• Fosun Industrial Co., Limited and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (collectively, "Fosun") beneficially own 10,716,630 shares of Butterfly Network, Inc.'s Class A common stock.
• This represents 4.7% of the outstanding Class A common stock.
• The ownership percentage is calculated based on 226,175,175 shares outstanding as of October 21, 2025, as reported in Butterfly Network's Form 10-Q filed on October 31, 2025.
• Fosun Industrial is a Hong Kong-based company engaged in foreign investment, sale, and consultancy services for Chinese and Western medicine, diagnostic reagents, and medical devices.
• Fosun Pharma is a leading innovation-driven global healthcare company operating in pharmaceuticals, medical devices & diagnostics, and healthcare services, incorporated in the People's Republic of China.
• The shares are held for investment purposes and not with the intent to change or influence control of Butterfly Network, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. A significant stake by a reputable global healthcare conglomerate like Fosun can be interpreted as a vote of confidence in Butterfly Network's technology and market potential, even if the investment is passive.

Positives

• A significant stake (4.7%) by a global healthcare and pharmaceutical conglomerate like Fosun could signal confidence in Butterfly Network's long-term prospects and technology.
• Fosun's expertise in medical devices and diagnostics aligns strategically with Butterfly Network's business, potentially opening doors for future collaborations or market access.

Risks

• No specific risks related to Butterfly Network's operations or financial health are disclosed in this ownership report.
• The filing does not indicate any intent by Fosun to influence the control of the issuer, which could be a risk if a strategic investor were to become activist.

Future Outlook

The filing is a beneficial ownership report and does not contain forward-looking statements or guidance regarding Butterfly Network, Inc.'s future operations or financial performance.

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

StockSavvy.ai notes that the disclosure of a 4.7% stake by Fosun, a major global healthcare and pharmaceutical entity, could be viewed positively by the market. This investment by a strategic player in the medical device and diagnostics space suggests potential validation of Butterfly Network's technology and market position, especially given Fosun's stated business activities in these areas. It could also hint at future strategic partnerships or collaborations, aligning with broader industry trends of established healthcare giants investing in innovative medical technology companies.

Comparison to Industry Standards

• This filing is a beneficial ownership report, not a financial performance report, so direct comparison of results to industry standards or specific comparable companies is not applicable.
• StockSavvy.ai observes that a 4.7% stake by a large, diversified healthcare group like Fosun (which has a global presence and significant investments in pharmaceuticals, medical devices, and diagnostics) is a notable endorsement for a company like Butterfly Network, which operates in the innovative medical imaging space. While not a controlling stake, it positions Fosun as a significant passive investor, potentially signaling long-term strategic interest.

Stakeholder Impact

• Shareholders: The presence of a significant institutional investor like Fosun could enhance investor confidence and potentially stabilize the stock.
• Employees: No direct impact mentioned, but potential future collaborations could create opportunities.
• Customers/Suppliers: No direct impact mentioned.

Key Dates

Recommendation

While the disclosure of a significant stake by a strategic healthcare investor like Fosun is generally positive, this Schedule 13G filing indicates a passive investment without intent to influence control. It provides a vote of confidence but does not inherently suggest immediate catalysts for substantial price appreciation or depreciation based solely on this report. Investors should 'hold' and monitor for any further strategic developments or changes in Fosun's stake, alongside Butterfly Network's operational performance.

Keywords

Butterfly Network, Fosun Industrial, Shanghai Fosun Pharmaceutical, Class A common stock, beneficial ownership, SEC filing, Schedule 13G, healthcare investment, medical devices, diagnostics